Jeremy Bender Sells 13,964 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender sold 13,964 shares of the company’s stock in a transaction on Friday, May 16th. The shares were sold at an average price of $6.26, for a total transaction of $87,414.64. Following the completion of the transaction, the chief executive officer now owns 145,737 shares of the company’s stock, valued at approximately $912,313.62. The trade was a 8.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Jeremy Bender also recently made the following trade(s):

• On Tuesday, February 18th, Jeremy Bender sold 12,048 shares of Day One Biopharmaceuticals stock. The stock was sold at an average price of $11.96, for a total transaction of $144,094.08.

Day One Biopharmaceuticals Stock Performance

Shares of Day One Biopharmaceuticals stock opened at $6.58 on Wednesday. The company has a market cap of $666.96 million, a P/E ratio of -6.39 and a beta of -1.24. Day One Biopharmaceuticals, Inc. has a one year low of $6.08 and a one year high of $16.76. The firm has a fifty day moving average of $7.36 and a two-hundred day moving average of $10.68.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.11. The company had revenue of $30.76 million during the quarter, compared to analysts’ expectations of $30.28 million. As a group, equities analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. decreased their price target on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a research note on Wednesday, March 5th. Needham & Company LLC decreased their price target on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. The Goldman Sachs Group decreased their price target on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating for the company in a research note on Tuesday, March 25th. Wedbush reiterated an “outperform” rating and set a $25.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday, May 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, April 3rd. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $30.57.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Large investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. purchased a new position in shares of Day One Biopharmaceuticals in the 4th quarter valued at about $27,000. R Squared Ltd purchased a new position in shares of Day One Biopharmaceuticals in the 4th quarter valued at about $31,000. Quantbot Technologies LP purchased a new position in shares of Day One Biopharmaceuticals in the 1st quarter valued at about $82,000. Tower Research Capital LLC TRC increased its holdings in shares of Day One Biopharmaceuticals by 911.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock valued at $135,000 after purchasing an additional 9,603 shares in the last quarter. Finally, Pallas Capital Advisors LLC purchased a new position in shares of Day One Biopharmaceuticals in the 1st quarter valued at about $87,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.